CD19 specific chimeric antigen receptor (CAR) T-cell therapy with patient-derived T-cells is now established as novel and effective treatment for relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL) [1] and demonstrated efficacy in r/r large B-cell lymphoma (LBCL) [2–4], follicular lymphoma (FL) [3, 4], and mantle-cell lymphoma (MCL) [5]. Here, CD19 is linked to non-Hodgkin lymphoma.